Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-r6qrq Total loading time: 0 Render date: 2024-04-28T15:50:27.469Z Has data issue: false hasContentIssue false

Chapter 8 - Neuropsychiatric (Behavioral) Symptoms in Parkinson’s Disease

Published online by Cambridge University Press:  05 March 2022

By
Kasia Gustaw Rothenberg
Edited by
Néstor Gálvez-Jiménez ,
Amos D. Korczyn  and
Ramón Lugo-Sanchez
Néstor Gálvez-Jiménez
Affiliation:
Florida International University
Amos D. Korczyn
Affiliation:
Tel-Aviv University
Ramón Lugo-Sanchez
Affiliation:
Cleveland Clinic
Get access

Summary

Parkinson’s disease (PD) has traditionally been considered a motor system disorder, but it is now widely recognized to be a complex one with diverse clinical features that include neuropsychiatric manifestations [1]. Psychiatric features of PD include but are not limited to cognitive impairment, psychosis, anxiety, depression, apathy, sleep disturbances, as well as fatigue. In a multicenter survey of over 1000 patients with PD, virtually all (97%) of patients reported nonmotor symptoms, with each patient experiencing an average of approximately eight different ones [2].

Certain non-motor features of PD (e.g. olfactory dysfunction, constipation, depression, anxiety, and REM sleep behavior disorder) may even precede manifestation of motor symptoms [3, 4]. Psychiatric symptoms, especially psychosis and/or dementia, may be even more disabling than motor features [5, 6]

Type
Chapter
Information
Non-motor Parkinson's Disease , pp. 78 - 90
Publisher: Cambridge University Press
Print publication year: 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Gallagher, DA, Schrag, A. Psychosis, apathy, depression and anxiety in Parkinson’s disease. Neurobiol Dis 2012; 46: 581–589.CrossRefGoogle ScholarPubMed
Barone, P, Antonini, A, Colosimo, C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 2009; 24(11): 1641–1649.CrossRefGoogle ScholarPubMed
Lin, YQ, Chen, SD. RBD: a red flag for cognitive impairment in Parkinson’s disease? Sleep Med 2018; 44: 38.Google Scholar
Marsh, L, Williams, JR, Rocco, M, et al. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 2004; 63: 293–300.CrossRefGoogle ScholarPubMed
Rothenberg, KG. Assessment and management of psychiatric symptoms in neurodegenerative disorders (chapter 23) In: Babak T, Cummings J (eds.)., Neuro-Geriatrics. Springer International Publishing AG; 2017.Google Scholar
Rothenberg, KG, Rajaram, R. Advances in management of psychosis in neurodegenerative diseases. Curr Treat Options Neurol 2019; 21(1): 3.Google Scholar
Blonder, LX, Slevin, JT. Emotional dysfunction in Parkinson’s disease. Behav Neurol 2011; 24(3): 201–217.CrossRefGoogle ScholarPubMed
Stoyka, LE, Arrant, AE, Thrasher, DR, et al. Behavioral defects associated with amygdala and cortical dysfunction in mice with seeded α-synuclein inclusions. Neurobiol Dis 2020; 134: 104708: 1–11.Google Scholar
Bohnen, NI, Kaufer, DI, Hendrickson, R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia. J Neurol 2006; 253: 242.Google Scholar
Shimada, H, Hirano, S, Shinotoh, H, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 2009; 73: 273.CrossRefGoogle ScholarPubMed
Ehrt, U, Broich, K, Larsen, JP, et al. Use of drugs with anticholinergic effect and impact on cognition in Parkinson’s disease: a cohort study. J Neurol Neurosurg Psychiatry 2010; 81: 160.Google Scholar
Devos, D, Moreau, C, Maltête, D, et al. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson’s disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatry 2014; 85(6): 668–674.CrossRefGoogle ScholarPubMed
Dubois, B, Tolosa, E, Katzenschlager, R, et al. Donepezil in Parkinson’s disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord 2012; 27: 1230–1238.CrossRefGoogle ScholarPubMed
Ekman, U, Eriksson, J, Forsgren, L, et al. Functional brain activity and presynaptic dopamine uptake in patients with Parkinson’s disease and mild cognitive impairment: a cross-sectional study. Lancet Neurol 2012; 11: 679–687.CrossRefGoogle ScholarPubMed
Marini, P, Ramat, S, Ginestroni, A, Paganini, M. Deficit of short-term memory in newly diagnosed untreated parkinsonian patients: reversal after L-dopa therapy. Neurol Sci 2003; 24: 184.Google Scholar
Morrison, CE, Borod, JC, Brin, MF, et al. Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson’s disease (MSPD). J Neural Transm 2004; 111: 1333.CrossRefGoogle ScholarPubMed
Bohnen, NI, Albin, RL, Müller, ML, et al. Frequency of cholinergic and caudate nucleus dopaminergic deficits across the pre-demented cognitive spectrum of Parkinson disease and evidence of interaction effects. JAMA Neurol 2015; 72: 194.Google Scholar
Murai, T, Muller, U, Werheid, K, et al. In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2001; 13: 222–228.Google Scholar
Huot, P, Johnston, TH, Darr, T, et al. Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov Disord 2010; 25: 1399–1408.CrossRefGoogle ScholarPubMed
Ballanger, B, Strafella, AP, van Eimeren, T, et al. Serotonin 2 A receptors and visual hallucinations in Parkinson disease. Arch Neurol 2010; 67: 416.Google Scholar
Poletti, M, Frosini, D, Pagni, C, et al. Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 2012; 83: 601–606.CrossRefGoogle ScholarPubMed
Cummings, J, Ritter, A, Rothenberg, KG. Advances in management of neuropsychiatric syndromes in neurodegenerative diseases. Curr Psychiatry Rep 2019; 21(8): 79.CrossRefGoogle ScholarPubMed
Rothenberg, KG, Wiechers, IR. Antipsychotics for neuropsychiatric symptoms of dementia – safety and efficacy in the context of informed consent. Psychiatr Ann 2015; 45(7): 348–353.Google Scholar
Litvan, I, Goldman, JG, Tröster, AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012; 27(3): 349–356.Google Scholar
Weintraub, D, Simuni, T, Caspell-Garcia, C, et al. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson’s disease. Mov Disord 2015; 30: 919.Google Scholar
Emre, M, Aarsland, D, Brown, R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 2007; 22: 1689–1707.Google Scholar
Svenningsson, P, Westman, E, Ballard, C, Aarsland, D. Cognitive impairment in patients with Parkinson’s disease: diagnosis, biomarkers, and treatment. Lancet Neurol 2012; 11: 697.Google Scholar
Aarsland, D, Zaccai, J, Brayne, C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord 2005; 20: 1255.Google Scholar
Buter, TC, van den Hout, A, Matthews, FE, et al. Dementia and survival in Parkinson disease: a 12-year population study. Neurology 2008; 70(13): 1017–1022.Google Scholar
Hely, MA, Reid, WG, Adena, MA, et al. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837.Google Scholar
Levy, G, Schupf, N, Tang, MX, et al. Combined effect of age and severity on the risk of dementia in Parkinson’s disease. Ann Neurol 2002; 51: 72.CrossRefGoogle ScholarPubMed
Anang, JB, Gagnon, JF, Bertrand, JA, et al. Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology 2014; 83(14): 1253–1260.Google Scholar
Liu, G, Boot, B, Locascio, JJ, et al. Specifically neuropathic Gaucher’s mutations accelerate cognitive decline in Parkinson’s. Ann Neurol 2016; 80: 674.Google Scholar
Obi, T, Nishioka, K, Ross, OA, et al. Clinicopathologic study of a SNCA gene duplication patient with Parkinson disease and dementia. Neurology 2008; 70: 238.Google Scholar
Williams-Gray, CH, Evans, JR, Goris, A, et al. The distinct cognitive syndromes of Parkinson’s disease: 5-year follow-up of the CamPaIGN cohort. Brain 2009; 132: 2958–2969.Google Scholar
Morley, JF, Xie, SX, Hurtig, HI, et al. Genetic influences on cognitive decline in Parkinson’s disease. Mov Disord 2012; 27: 512–518.Google Scholar
Lin, CH, Fan, JY, Lin, HI, et al. Catechol-O-methyltransferase (COMT) genetic variants are associated with cognitive decline in patients with Parkinson’s disease. Parkinsonism Relat Disord 2018; 50: 48–53.Google Scholar
Grünewald, A, Kasten, M, Ziegler, A, Klein, C. Next-generation phenotyping using the parkin example: time to catch up with genetics. JAMA Neurol 2013; 70: 1186.CrossRefGoogle ScholarPubMed
Fang, L, Tang, BS, Fan, K, et al. Alzheimer’s disease susceptibility genes modify the risk of Parkinson disease and Parkinson’s disease-associated cognitive impairment. Neurosci Lett 2018; 677: 55–59.Google Scholar
Hindle, JV. The practical management of cognitive impairment and psychosis in the older Parkinson’s disease patient. J Neural Transm 2013; 120: 649–653.CrossRefGoogle ScholarPubMed
Seppi, K, Weintraub, D, Coelho, M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 2011; 26 Suppl 3: 42–80.CrossRefGoogle ScholarPubMed
Connolly, BS, Fox, SH. Drug treatments for the neuropsychiatric complications of Parkinson’s Disease. Expert Rev Neurother 2012; 12: 1439–1449.Google Scholar
Emre, M, Aarsland, D, Albanese, A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351: 2509–2518.Google Scholar
Maidment, I, Fox, C, Boustani, M. Cholinesterase inhibitors for Parkinson’s disease dementia. Cochrane Database Syst Rev 2006; 25(1): CD004747.Google Scholar
Minett, TS, Thomas, A, Wilkinson, LM, et al. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson’s disease with dementia. Int J Geriatr Psychiatry 2003; 18: 988.Google Scholar
Aarsland, D, Ballard, C, Walker, Z, et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009; 8: 613–618.Google Scholar
Wang, HF, Yu, JT, Tang, SW, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry 2015; 86: 135–143.Google Scholar
Monastero, R, Camarda, C, Pipia, C, Camarda, R. Visual hallucinations and agitation in Alzheimer’s disease due to memantine: report of three cases. J Neurol Neurosurg Psychiatry 2007; 78(5): 546.CrossRefGoogle ScholarPubMed
Weintraub, D, Burn, D. Parkinson’s disease: the quintessential neuropsychiatric disorder. Mov Disord 2011; 26(6): 1022–1031.Google Scholar
Troeung, L, Egan, SJ, Gasson, N. A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson’s disease. PLoS One 2013; 8(11): e79510.Google Scholar
Barone, P, Scarzella, L, Marconi, R, et al. Depression/Parkinson Italian Study Group. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized study. J Neurol 2006; 253(5): 601–607.CrossRefGoogle Scholar
Richard, IH, McDermott, MP, Kurlan, R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012; 78(16): 1229–1236.Google Scholar
Mulin, E, Leone, E, Dujardin, K, et al. Diagnostic criteria for apathy in clinical practice. Int J Geriatr Psychiatry 2011; 26(2): 158–165.Google Scholar
Dujardin, K, Sockeel, P, Delliaux, M, et al. Apathy may herald cognitive decline and dementia in Parkinson’s disease. Mov Disord 2009; 24: 2391–2397.Google Scholar
Mendonça, DA, Menezes, K, Jog, MS. Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. Mov Disord 2007; 22: 2070.Google Scholar
Zesiewicz, TA, Sullivan, KL, Arnulf, I, et al. Practice parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010; 74: 924.Google Scholar
Ondo, WG, Fayle, R, Atassi, F, Jankovic, J. Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry 2005; 76: 1636.Google Scholar
American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 5th ed. American Psychiatric Association; 2013.Google Scholar
Ravina, B, Marder, K, Fernandez, HH, et al. Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group. Mov Disord 2007; 22: 1061–1068.Google Scholar
Fenelon, G, Soulas, T, Zenasni, F, de Langavant, LC. The changing face of Parkinson’s disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord 2010; 25: 755–759.Google Scholar
Fenelon, G, Alves, G. Epidemiology of psychosis in Parkinson’s disease. J Neurol Sci 2010; 289: 12–17.CrossRefGoogle ScholarPubMed
Goetz, CG. New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson’s disease. Mov Disord 2010; 25 Suppl 1: 104–109.Google Scholar
Goldman, JG, Holden, S. Treatment of psychosis and dementia in Parkinson’s disease. Curr Treat Options Neurol 2014; 16(3): 281–299.CrossRefGoogle ScholarPubMed
Moretti, R, Torre, P, Antonello, RM, et al. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer’s disease and other dementias: a 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen 2003; 18: 205–214.Google Scholar
Pollak, P, Tison, F, Rascol, O, et al. Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004; 75(5): 689–695.CrossRefGoogle ScholarPubMed
Morgante, L, Epifanio, A, Spina, E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004; 27(4): 153–156.Google Scholar
Desmarais, P, Massoud, F, Filion, J, Nguyen, QD, Bajsarowicz, P. Quetiapine for psychosis in Parkinson disease and neurodegenerative parkinsonian disorders: a systematic review. J Geriatr Psychiatry Neurol 2016; 29(4): 227–236.Google Scholar
Hausner, L, Damian, M, Sartorius, A, Frolich, L. Efficacy and cognitive side effects of ECT in depressed elderly inpatients with co-existing mild cognitive impairment or dementia. J Clin Psychiatry 2011; 72: 91–97.CrossRefGoogle ScholarPubMed
Cummings, J, Isaacson, S, Mills, R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 2014; 383(9916): 533–540.Google Scholar
Weintraub, D, Claassen, DO. Impulse control and related disorders in Parkinson’s disease. Int Rev Neurobiol 2017; 133: 679–717.Google Scholar
Martini, A, Dal Lago, D, Edelstyn, NMJ, Grange, JA, Tamburin, S. Impulse control disorder in Parkinson’s disease: a meta-analysis of cognitive, affective, and motivational correlates. Front Neurol 2018; 28(9): 654.Google Scholar
Thomas, A, Bonanni, L, Gambi, F, Di Iorio, A, Onofrj, M. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 2010; 68(3): 400–404.Google Scholar
Papay, K, Xie, SX, Stern, M, et al. Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology 2014; 83(9): 826–833.Google Scholar
Zhang, G, Zhang, Z, Liu, L, et al. Impulsive and compulsive behaviors in Parkinson’s disease. Front Aging Neurosci 2014; 6: 318.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×